Aspira Women’s Health appoints new CEO and VP of Finance

AUSTIN, Texas-based Aspira Women’s Health Inc. (NASDAQ:AWH), a company specializing in in vitro and in vivo diagnostic substances with annual revenue of $8.96 million, announced executive leadership changes in a recent filing with the U.S. Securities and Exchange Commission.

According to InvestingPro data, the company currently operates with a market capitalization of $6.7 million and faces challenges with cash burn and short-term obligations exceeding liquid assets.

On January 28, 2025, Michael Buhle was appointed as the Chief Executive Officer, expanding his role from Chief Commercial Officer. Additionally, James Crawford was named Vice President of Finance, taking on the roles of principal financial officer and principal accounting officer.

Michael Buhle, 59, brings over 25 years of experience in commercial growth and product launches within the diagnostics sector. His previous positions include Chief Commercial Officer at Biovision Diagnostics and Vice President of Sales, Americas at Congenica. There are no familial ties or material interests in any transactions involving Buhle that would require disclosure under SEC regulations.

Dr. Sandra Milligan, who served as Interim CEO, will continue as the company’s President, guiding the strategic direction alongside Buhle.

James Crawford, 39, has been with Aspira since 2021, initially as Manager, Financial Planning & Analysis. With a background in finance across various industries, Crawford holds a Bachelor of Science degree from Bucknell University and a Master’s degree from the University of Connecticut.

Similar to Buhle, Crawford has no familial relationships or material transactions with the company that necessitate reporting under SEC regulations.

These leadership appointments come at a time when Aspira Women’s Health faces significant market challenges, with InvestingPro analysis showing a 92.56% decline in stock value over the past year. The company has not disclosed any additional details regarding compensation arrangements for the newly appointed officers. InvestingPro’s analysis indicates the stock is currently trading below its Fair Value, though analysts do not anticipate profitability this year.

Aspira Women’s Health, formerly known as Vermillion , Inc., and before that as Ciphergen Biosystems Inc. and Abiotic Systems, is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol (NASDAQ:AWH). For deeper insights into AWH’s financial health, valuation metrics, and expert analysis, investors can access the comprehensive Pro Research Report available exclusively on InvestingPro, which covers over 1,400 US stocks with detailed financial analysis and actionable intelligence.

This information is based on a press release statement filed with the SEC.

In other recent news, Aspira Women’s Health has seen considerable developments. The company’s Interim Chief Financial Officer, John Kallassy, has resigned, with the CEO, Dr. Sandra Milligan, assuming his duties. This transition comes amid financial challenges, as indicated by a concerning cash burn rate and a current ratio of 0.75. Furthermore, the company faces the threat of Nasdaq delisting due to failure to meet the minimum Market Value of Listed Securities requirement.

On a brighter note, Aspira reported a 2% growth in OvaSuite revenue, reaching $2.3 million in Q3 2024, and a 4% increase in test volume. The company also announced a significant collaboration on ovarian cancer detection and a $10 million federal award from ARPA-H for the development of ENDOinform, a test for endometriosis.

Aspira is focusing on expanding its ovarian cancer portfolio and enhancing commercial capabilities, partnering with Dana-Farber Cancer Institute and Harvard Medical (TASE:PMCN) School. The company plans to accelerate the development of ENDOinform and OVAinform with ARPA-H support.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.